Protease-activated receptor antagonist for reducing cardiovascular events – A review on Vorapaxar - Gupta, R; Lin, M; Mehta, A; Aedma, S K; Shah, R; Ranchal, P; Vyas, A V; Singh, S; Kluck, B; Combs, W G; Patel, N C (Curr Probl Cardiol, 2023)